Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017
At the ATS meeting today, investigators presented pivotal clinical validation study results confirming the Envisia classifier's ability to detect usual interstitial pneumonia (UIP), a pattern whose presence is essential to IPF diagnosis, without the need for surgery. The genomic test identified UIP vs. non-UIP with high specificity of nearly 90% and demonstrated sensitivity of 67 percent, meaning it would be expected to identify two thirds of UIP cases with a high degree of accuracy. This performance was compared to a reference standard of histopathology review by a central panel of pathologists with expertise in ILD. The findings are from the 30-site, prospective BRAVE trial and involved 236 transbronchial biopsy (TBB) samples from 49 patients.
"By providing information that today can often only be obtained through surgery, the Envisia classifier has the potential of enabling the diagnosis of IPF," said
Data were also presented from an analytical verification study demonstrating the Envisia classifier's strong accuracy, reproducibility, and robustness in distinguishing UIP from non-UIP under conditions that emulate the operational and biological variation that may be encountered in routine testing. The study included assessing the classifier's ability to determine gene expression in a pooled RNA sample composed of multiple (3-5) TBB samples per patient, with varying mixtures of each sample, illustrating that the test is robust across sampling variations.
"The data presented today demonstrate the significant role that the Envisia Genomic Classifier can play in resolving uncertainty in IPF diagnosis so that patients can get the answers they need without undergoing surgery," said
About Interstitial Lung Disease
Each year in
About the Envisia Genomic Classifier
The Envisia Genomic Classifier is designed to improve physicians' ability to differentiate IPF from other ILDs without the need for surgery. The 190-gene classifier uses machine learning coupled with powerful, deep RNA sequencing to detect the presence or absence of usual interstitial pneumonia, or UIP, a classic diagnostic pattern whose presence is essential for the diagnosis of IPF, using samples obtained through less-invasive bronchoscopy.
About Veracyte
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expected," "can," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our estimate of the number of patients who have avoided unnecessary surgery, our beliefs regarding the potential benefits of our tests to patients, physicians and payers and our beliefs regarding the market opportunity for our products. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our
business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: demand for our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; the size of the market opportunity for our products; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and
outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-announces-clinical-validation-data-demonstrating-envisia-genomic-classifiers-performance-in-improving-idiopathic-pulmonary-fibrosis-diagnosis-presented-at-ats-2017-300462574.html
SOURCE
News Provided by Acquire Media